They observed that the median leukemia free survival was significantly shorter in the subset of patients with p53 overexpression (9 vs 55 months; p = 0.026), including those who were consolidated with allogeneic stem-cell transplantation (ASCT) (32). The gene discussed is TP53; the disease is leukemia.